198 related articles for article (PubMed ID: 31656659)
1. Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer.
Del Valle MFF; Chang AY
J Thorac Dis; 2019 Sep; 11(9):3864-3873. PubMed ID: 31656659
[TBL] [Abstract][Full Text] [Related]
2. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
Aguado de la Rosa C; Cruz Castellanos P; Lázaro-Quintela M; Dómine M; Vázquez Estévez S; López-Vivanco G; Fírvida Pérez JL; Alonso Romero JL; Ferrera Delgado L; García Girón C; Diz Taín P; Álvarez Álvarez R; Mut Sanchís P; Fernández Cantón I; Manrique Abós I; Martínez Aguillo M; Gómez-Aldaraví Gutiérrez L; Ortega Granados AL; Álvarez Cabellos R; García Sebastián A; García Sifuentes LF; Reguart N
Lung Cancer; 2022 Nov; 173():83-93. PubMed ID: 36162227
[TBL] [Abstract][Full Text] [Related]
3. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
4. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.
Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2016 Jul; 97():43-7. PubMed ID: 27237026
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer: Multicenter retrospective analysis in South Korea.
Jeon DS; Park CK; Kim SJ; Park CK; Chang YS; Jung CY; Lee SY; Lee SY; Ryu JS; Lee JE; Lee KY; Jang TW; Jang SH; Yoon SH; Lee SH; Choi CM; Kim HR; Kim YJ
Thorac Cancer; 2024 Feb; 15(6):448-457. PubMed ID: 38171544
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases.
Zanwar S; Noronha V; Joshi A; Patil VM; Kaushal R; Chougule A; Janu A; Mahajan A; Kapoor A; Prabhash K
Indian J Cancer; 2017; 54(4):678-680. PubMed ID: 30082557
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.
Lei YY; Yang JJ; Zhong WZ; Chen HJ; Yan HH; Han JF; Yang LL; Wu YL
J Thorac Dis; 2015 Jul; 7(7):1181-8. PubMed ID: 26380734
[TBL] [Abstract][Full Text] [Related]
9. Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.
Miloš P; Jana S; Vítězslav K; Monika Š; Leona K; Jaromír R; Renata C; Markéta Č; Andrea B; Juraj K; Michal H; Milada Z; Marek K; Helena Č; Martin S
Klin Onkol; 2018; 31(3):207-212. PubMed ID: 30441974
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings.
Kapoor A; Noronha V; Patil V; Menon N; Nandhana R; Kumar A; Mahajan A; Janu A; Kumar R; Prabhash K
South Asian J Cancer; 2023 Apr; 12(2):179-184. PubMed ID: 37969671
[TBL] [Abstract][Full Text] [Related]
11. Distinct metastatic spread and progression patterns in patients treated with crizotinib for
Nakamura T; Yoshida T; Takeyasu Y; Masuda K; Sinno Y; Matsumoto Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
Transl Lung Cancer Res; 2023 Jul; 12(7):1436-1444. PubMed ID: 37577313
[TBL] [Abstract][Full Text] [Related]
12. Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center.
Liu C; Yu H; Long Q; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Chang J; Wang J
Front Oncol; 2019; 9():1116. PubMed ID: 31696059
[No Abstract] [Full Text] [Related]
13. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
14. Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study.
Yang G; Ma D; Xu H; Yang L; Li J; Xing P; Hao X; Wang Y
Cancer Med; 2019 Oct; 8(13):5823-5830. PubMed ID: 31407528
[TBL] [Abstract][Full Text] [Related]
15. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
16. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
17. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.
Xing P; Wang S; Wang Q; Ma D; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang L; Liang H; Du Y; Zhang Z; Li J
Target Oncol; 2019 Jun; 14(3):325-333. PubMed ID: 31025247
[TBL] [Abstract][Full Text] [Related]
19. Impact of crizotinib on long-term survival of
Xing P; Ma D; Wang Q; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang L; Liang H; Du Y; Zhang Z; Li J
Chin J Cancer Res; 2019 Jun; 31(3):481-488. PubMed ID: 31354217
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
Zhou J; Zheng J; Zhang X; Zhao J; Zhu Y; Shen Q; Wang Y; Sun K; Zhang Z; Pan Z; Shen Y; Zhou J
BMC Cancer; 2018 Jan; 18(1):10. PubMed ID: 29298713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
